Kyowa Kirin Discontinues Rocatinlimab Trials Due To Malignancy Risk

Amgen Had Recently Returned Asset

 
• By Lisa Takagi
  
Kyowa kirin discontinues rocatinlimab
The Japanese firm overturned their positive risk-safety assessment after discovering another Kaposi's sarcoma cases which suggest their potential link to OX40 pathway. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Japan

More from Focus On Asia